ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2014
Pharmacokinetics of sustained-release analgesics in mice.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pharmacodynamic characteristics and influencing factors of tapentadol for chronic pain relief under dose titration.Frontiers in pain research (Lausanne, Switzerland) · 2024Pooled it
- Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Evaluation of a human slow-release buprenorphine formulation in rats - tactile sensitivity and plasma concentration.Laboratory animal research · 2026Article
- Pharmacokinetics and Analgesic Efficacy of a Novel Extended-Release Buprenorphine Formulation in Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Suitability of prolonged meloxicam treatment in mice seems limited due to unfavorable pharmacokinetics, side effects, and impact on home-cage behaviors.Scientific reports · 2025Article
- The Analgesic Effect of Two Different Extended-Release Meloxicam Formulations for Attenuation of Hypersensitivity in Rats (Rattus norvegicus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Evaluation of Extended- and Immediate-Release Buprenorphine Formulations on Pharmacokinetics and Injection Site Lesions in Different Strains and Sex of Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures.Scientific reports · 2024Article
- Pharmacokinetics of Injectable Meloxicam and Buprenorphine in the Naked Mole-Rat (Journal of the American Association for Laboratory Animal Science : JAALAS · 2024Article
- Pharmacokinetic Evaluation of a Topical Extended-release Analgesic in Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2024Article
- Antinociceptive and Cardiorespiratory Effects of a Single Dose of Dexmedetomidine in Laboratory Mice Subjected to Craniotomy under General Anaesthesia with Isoflurane and Carprofen or Meloxicam.Animals : an open access journal from MDPI · 2024Article
- Subcutaneous and orally self-administered high-dose carprofen shows favorable pharmacokinetic and tolerability profiles in male and female C57BL/6J mice.Frontiers in veterinary science · 2024Article
- Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed.Veterinary sciences · 2023Review
- A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models.Scientific reports · 2023Article
- High-dose Meloxicam Provides Improved Analgesia in Female CD1 Mice: A Pharmacokinetic and Efficacy Study.Journal of the American Association for Laboratory Animal Science : JAALAS · 2023Article
- A Review of Long-acting Parenteral Analgesics for Mice and Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2022Review
- Effects of Transdermal Fentanyl Treatment on Acute Pain and Inflammation in Rats with Adjuvant-induced Monoarthritis.Comparative medicine · 2022Article
- Pharmacokinetics of Sustained-release and Extended-release Buprenorphine in Mice after Surgical Catheterization.Journal of the American Association for Laboratory Animal Science : JAALAS · 2022Article
- Efficacy of 3 Buprenorphine Formulations for the Attenuation of Hypersensitivity after Plantar Incision in Immunodeficient NSG Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Buprenorphine and carprofen, 2 of the most commonly used analgesics in mice, must be administered every 8 to 12 h to provide sustained analgesia. Sustained-release (SR) formulations of analgesics maintain plasma levels that should be sufficient to provide sustained analgesia yet require less frequent dosing and thus less handling of and stress to the animals. The pharmacokinetics of SR formulations of buprenorphine (Bup-SR), butorphanol (Butp-SR), fentanyl (Fent-SR), carprofen (Carp-SR), and meloxicam (Melox-SR) were evaluated in mice over 72 h and compared with those of traditional, nonSR formulations. Bup-SR provided plasma drug levels greater than the therapeutic level for the first 24 to 48 h after administration, but plasma levels of Bup-HCl fell below the therapeutic level by 4 h. Fent-SR maintained plasma levels greater than reported therapeutic levels for 12 h. Therapeutic levels of the remaining drugs are unknown, but Carp-SR provided plasma drug levels similar to those of Carp for the first 24 h after administration, whereas Melox-SR had greater plasma levels than did Melox for the first 8 h. Butp-SR provided detectable plasma drug levels for the first 24 h, with a dramatic decrease over the first 4 h. These results indicate that Bup-SR provides a stable plasma drug level adequate for analgesia for 24 to 48 h after administration, whereas Carp-SR, Melox-SR, Fent-SR, and Butp-SR would require additional doses to provide analgesic plasma levels beyond 24 h in mice.
Indexed as
Identifiers
25255070PMC4181689W2295943482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.